The technology transfer, formalized through a contract signed in March, enables BioLAB to independently conduct chromosome analysis and fluorescence in situ hybridization (FISH) tests. Over 16 weeks, GC Green Cross provided an intensive training program to equip BioLAB’s staff with the necessary skills. The foundation also plans to dispatch specialized personnel to Bahrain to ensure the technology is fully integrated into local operations, moving beyond mere transfer to support on-the-ground implementation.
Historically, BioLAB has outsourced over 150 chromosome analysis cases to GC Green Cross due to growing demand for such diagnostics in Bahrain. By establishing in-house testing capabilities, BioLAB expects to significantly reduce the time and cost associated with transporting samples abroad, while also accelerating patient care delivery.
“This collaboration is less about short-term profits and more about laying the groundwork for long-term global strategy,” said Sang-Gon Lee, president of GC Green Cross Medical Foundation. “We see this as a stepping stone to building a broader global medical network.”
The move underscores South Korea’s growing influence in the global healthcare sector, as its institutions increasingly share cutting-edge diagnostic technologies with international partners.
Kim Kuk Ju, HEALTH IN NEWS TEAM
press@hinews.co.kr
